Home Other Building Blocks ILK-IN-1

ILK-IN-1

CAS No.:
1333146-24-9
Catalog Number:
AG009CIH
Molecular Formula:
C30H30F3N5O
Molecular Weight:
533.5873
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
2mg
98%
1 week
United States
$307
- +
5mg
98%
1 week
United States
$585
- +
10mg
98%
1 week
United States
$890
- +
Product Description
Catalog Number:
AG009CIH
Chemical Name:
ILK-IN-1
CAS Number:
1333146-24-9
Molecular Formula:
C30H30F3N5O
Molecular Weight:
533.5873
MDL Number:
MFCD29472239
IUPAC Name:
N-methyl-3-[1-(4-piperazin-1-ylphenyl)-5-[4-[4-(trifluoromethyl)phenyl]phenyl]pyrazol-3-yl]propanamide
InChI:
InChI=1S/C30H30F3N5O/c1-34-29(39)15-10-25-20-28(38(36-25)27-13-11-26(12-14-27)37-18-16-35-17-19-37)23-4-2-21(3-5-23)22-6-8-24(9-7-22)30(31,32)33/h2-9,11-14,20,35H,10,15-19H2,1H3,(H,34,39)
InChI Key:
GHBUPSVATJKTRR-UHFFFAOYSA-N
SMILES:
CNC(=O)CCc1nn(c(c1)c1ccc(cc1)c1ccc(cc1)C(F)(F)F)c1ccc(cc1)N1CCNCC1
Properties
Complexity:
767  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
533.24g/mol
Formal Charge:
0
Heavy Atom Count:
39  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
533.599g/mol
Monoisotopic Mass:
533.24g/mol
Rotatable Bond Count:
7  
Topological Polar Surface Area:
62.2A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
5.1  
Literature
Title Journal
Identification and characterization of a novel integrin-linked kinase inhibitor. Journal of medicinal chemistry 20110922
Integrin-linked kinase overexpression and its oncogenic role in promoting tumorigenicity of hepatocellular carcinoma. PloS one 20110101
Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer. Oncogene 20100610
Tumor expression of integrin-linked kinase (ILK) correlates with the expression of the E-cadherin repressor snail: an immunohistochemical study in ductal pancreatic adenocarcinoma. Virchows Archiv : an international journal of pathology 20100301
ILK over-expression in human colon cancer progression correlates with activation of beta-catenin, down-regulation of E-cadherin and activation of the Akt-FKHR pathway. The Journal of pathology 20060101
Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid. The Journal of pathology 20031001
Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. The Journal of biological chemistry 20030620
Expression of integrin-linked kinase is closely correlated with invasion and metastasis of gastric carcinoma. Virchows Archiv : an international journal of pathology 20030201
Phosphorylation of the myosin phosphatase inhibitors, CPI-17 and PHI-1, by integrin-linked kinase. The Biochemical journal 20021015
Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. The Journal of biological chemistry 20010720
Integrin-linked kinase expression increases with prostate tumor grade. Clinical cancer research : an official journal of the American Association for Cancer Research 20010701
Ca2+-independent smooth muscle contraction. a novel function for integrin-linked kinase. The Journal of biological chemistry 20010511
Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America 20000328
Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proceedings of the National Academy of Sciences of the United States of America 19980915
Properties